KIDNEY MEDULLARY CARCINOMA
Clinical trials for KIDNEY MEDULLARY CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new KIDNEY MEDULLARY CARCINOMA trials appear
Sign up with your email to follow new studies for KIDNEY MEDULLARY CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy targets Hard-to-Treat urinary cancers
Disease control OngoingThis early-phase study tests two or three drugs together (cabozantinib, nivolumab, and sometimes ipilimumab) in people with advanced cancers of the urinary and genital systems that have spread. The main goals are to find the safest dose and understand side effects. About 152 adul…
Matched conditions: KIDNEY MEDULLARY CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 09:38 UTC
-
New hope for rare childhood cancers: immunotherapy combo shows promise
Disease control OngoingThis study tests two immunotherapy drugs, tiragolumab and atezolizumab, in children and adults whose rare cancers (like certain brain, kidney, and soft tissue tumors) have returned or not responded to treatment. These cancers lack specific genes (SMARCB1 or SMARCA4), making them …
Matched conditions: KIDNEY MEDULLARY CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 09:30 UTC
-
Could a radioactive drug plus standard therapy ease bone pain in advanced kidney cancer?
Disease control OngoingThis study tests whether adding a radioactive drug (radium-223) to the usual treatment (cabozantinib) helps people with advanced kidney cancer that has spread to the bones. About 134 adults with any type of kidney cancer and bone metastases will be randomly assigned to receive ca…
Matched conditions: KIDNEY MEDULLARY CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:03 UTC